Genia Turanova, Chief Investment Strategist for Game-Changing Stocks and Fast-Track Millionaire, is a financial writer and money manager whose experience includes serving for more than a decade as a portfolio manager and Investment Committee member for a New York-based money management firm. Genia also researched, wrote and managed recommendations for several investment advisories. From 2011 to 2016, she served as Editor of the award-winning Leeb Income Performance newsletter. Genia also wrote for The Complete Investor, another award winner, from 2003 to 2016. During that time, Genia was responsible for several portfolios, including the "Income/Value" portfolio and the "FastTrack" portfolio. Genia's academic credentials include an MBA in Finance and Investments from the Zicklin School of Business, Baruch College in New York City. Genia is a CFA Charterholder.
Analyst Articles
Amid all the trade-related headlines these days, it’s still crucial for us to keep up with new developments — regulatory or scientific — that could define or impact the future of many industries. After all, when a trade war is allowed to continue unchecked,… Read More
Last Friday, the tariff war started in earnest: the U.S. imposed $34 billion worth of tariffs on...
Read More
Last Friday, the tariff war started in earnest: the U.S. imposed $34 billion worth of tariffs on China and, in response, China said it applied its own tariffs on U.S. goods. —Recommended...
Read More
The stated aim of The Daily Paycheck has always been “to help you reach the goal of receiving a dividend check for every day of the year.” Dividend payments tend to be concentrated, of course, but I’m happy to report that the number of paychecks reinvested in The… Read More
At long last, the merger between AT&T (NYSE: T) and Time Warner (NYSE: TWX) has closed....
Read More
At long last, the merger between AT&T (NYSE: T) and Time Warner (NYSE: TWX) has closed. —Recommended Link— “I wish I’d done this 20 years ago.” That’s what a...
Read More
Last Friday, the tariff war started in earnest: the U.S. imposed $34 billion worth of tariffs on China and, in response, China said it applied its own tariffs on U.S. goods. A ship laden with U.S. soybeans raced to arrive at its… Read More
Despite rising volatility and a slew of concerns about the world at large, the market has done well enough so far this year, especially given its exponential advance over the past few years. The Russell 2000 small-cap index is up 9.8%, while the S&P… Read More
The threat of competition from Amazon (Nasdaq: AMZN) — which has for some time been weighing on shares of drugstore companies such as Walgreens Boots Alliance (NYSE: WAG) and our portfolio’s CVS Health (NYSE: CVS) — looks as if it may actually materialize. This… Read More
At long last, the merger between AT&T (NYSE: T) and Time Warner (NYSE: TWX) has closed. This act was completed on June 14. The telecom giant didn’t waste any time in taking control (after all, it had already waited as long as… Read More
Think fast: What’s the first thing that comes to mind when you’re asked to imagine a cloud? Is it the white puffy thing that floats over our heads? What about “the” cloud – the storing and accessing of data and programs over the internet… Read More
Shares of our portfolio’s Sarepta (Nasdaq: SRPT), a gene therapy biotech with a gene-editing product addressing Duchenne muscular dystrophy (DMD), jumped more than 55% on the just-reported breakthrough results of its clinical study. Sarepta’s experimental gene therapy was shown to dramatically increase the production… Read More
